Error loading player: No playable sources found

Coupling Mass Spectrometry (MS) with non-MS Assays for Automated Profiling of Antibody Impurities | Presented by Agilent Technologies

Date
January 30, 2025
This product is not available for individual purchase, but it is available as part of the following products:

Session Speaker:


Harsha GunawardenaJohnson & Johnson Innovative Medicine


Related Products

Thumbnail for Plenary Session 4 - Old Dog, New Tricks: Harnessing the Hidden Potential of Established Analytical Technologies to Drive Complex Product Characterization
Plenary Session 4 - Old Dog, New Tricks: Harnessing the Hidden Potential of Established Analytical Technologies to Drive Complex Product Characterization
Innovations in therapeutic modalities are continually emerging as viable treatment options for a multitude of disease indications…
Thumbnail for Parallel Session 5B - Immunogenicity Risk and Control
Parallel Session 5B - Immunogenicity Risk and Control
Peptides, proteins and oligonucleotide are becoming essential medical treatments for many progressive, debilitating, or life-threatening diseases. However, the development of these potential therapies can be derailed by product immunogenicity as it can impact on safety and efficacy…
Thumbnail for Parallel Session 6B: The Critical Need to Protect the Horseshoe Crab: Initiatives from Industry, Suppliers and Regulators to Replace the LAL Assay
Parallel Session 6B: The Critical Need to Protect the Horseshoe Crab: Initiatives from Industry, Suppliers and Regulators to Replace the LAL Assay
The pharmaceutical industry is increasingly viewed as a key sector systemically important in reversing nature loss.     One of the sector’s key dependencies is on the horseshoe crab , a species that is vital to marine ecosystems only located in a few locations globally…
Thumbnail for Parallel Session 2B- LER 2025: Strategies Today for Overcoming Low Endotoxin Recovery
Parallel Session 2B- LER 2025: Strategies Today for Overcoming Low Endotoxin Recovery
Monitoring and control of endotoxin are critical aspects of an overall microbial control strategy necessary to ensure drug product quality and patient safety…